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CASE REPORT Open Access
Macrophage type 2 differentiation in a
patient with laryngeal squamous cell
carcinoma and metastatic prostate
adenocarcinoma to the cervical lymph
nodes
Michael C. Topf1*, Madalina Tuluc2, Larry A. Harshyne3 and Adam Luginbuhl1
Abstract
Background: The tumor microenvironment often polarizes infiltrating macrophages towards a type 2, or M2 phenotype,
that is characterized by expression of various cysteine-rich, scavenger receptors, including CD163. The primary function of
M2 macrophages is to facilitate wound healing. As such, they are capable of providing metabolic support to a growing
tumor, neovascularization, as well as protection from cytotoxic T cells. The tumor microenvironment contains a milieu of
secreted factors and vesicles, which in certain circumstances can gain access to lymphatic vessels that drain
to local lymph nodes.
Case presentation: We report a 59-year-old male with recurrent T4 squamous cell carcinoma (SCC) of the larynx with
synchronous prostate adenocarcinoma confined to the prostate and regional pelvic lymph nodes, without metastatic
disease. The patient underwent salvage total laryngectomy and bilateral neck dissection with final pathology revealing a
recurrent moderately differentiated SCC involving the larynx as well as prostate cancer in draining level 4 cervical lymph
nodes bilaterally. CD163 staining was performed on the primary tumor, a negative draining lymph node, and a level four
lymph node with a focus of metastatic prostate cancer and compared to benign controls. The negative draining lymph
node demonstrated a large CD163 population of cells as did the interface of the focus of prostate cancer and surrounding
lymph node. CD163 levels were markedly increased in this patient compared to benign lymph node controls. The macrophage
differentiation at the primary tumor in the larynx was strongly CD163 positive supporting an immune permissive environment
for tumor growth and metastasis.
Conclusion:We describe a unique case of solitary metastatic prostate cancer to cervical lymph nodes in the setting of a
laryngeal cancer. These observations suggest that SCC-derived factors drive a tumor-supportive environment in draining
lymph nodes dominated by an overwhelming number of CD163+, M2 macrophages. Lymph nodes that are ‘primed’ by
SCC differentiation to M2 phenotype may be at higher risk of harboring metastases.
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Background
Macrophages are innate immune cells that are influenced
by factors present in the local microenvironment to guide
proper immune programs. In this capacity, macrophages
are found to have two main phenotypes: macrophage 1
(M1) and macrophage 2 (M2), which correspond to
respective T-helper cell subsets [1–4]. M1 macrophages
are activated by IFN-γ and secrete pro-inflammatory
cytokines such as IL-12 and tumor-necrosis factor alpha,
which support anti-tumor immune responses. Conversely,
M2 macrophages are activated by IL-4, IL-10, and IL-13
and secrete anti-inflammatory cytokines such as TGFβ
and IL10, and angiogenic factors such angiopoietin and
VEGF, which promote tumor growth, invasion, and
metastases. The balance between M1 and M2 macro-
phages is one of the many factors that allow a transition
from a cytotoxic lethal immune environment of a normal
lymph node to an immunotolerant environment that
allows tumors metastasis [1, 4].
Tumor-associated macrophages (TAMs) are key media-
tors in the tumor microenvironment by modulating
metabolic factor production and cytokine profiles within
the tumor microenvironment [1–4]. TAMs possess a
predominant M2 phenotype indicative of local immune
suppression [2, 5]. Previous studies have investigated the
balance between M1 and M2 macrophages in head and
neck squamous cell carcinoma (HNSCC) and found that
the majority of TAMs are predominantly the M2 pheno-
type [1, 6, 7]. Furthermore, increased M2 polarization has
been associated with decreased survival in HNSCC [8–11].
The CD163 protein belongs to a scavenger receptor
cysteine-rich family that is expressed on the surface of M2
macrophages and can be used as an immunohistochemical
marker for these cells [12].
In this case report, we describe a patient with a unique
clinical presentation of metastatic prostate cancer to
bilateral cervical lymph nodes in the setting of laryngeal
squamous cell carcinoma (SCC). We further investigated
the M2 differentiation of the draining cervical lymph
nodes. We hypothesize that the patient’s laryngeal SCC
was able to skew the local immune microenvironment to
a permissive atmosphere favoring tumor escape and
metastasis, allowing for his prostate cancer to spread to
the cervical lymph nodes.
Case presentation
A 59-year-old male with recurrent T4 N0 SCC of the
larynx with synchronous prostate adenocarcinoma was
referred to our clinic. His prostate adenocarcinoma was
confined to the prostate and regional pelvic lymph
nodes, without any known distant metastatic disease,
and was being treated with hormone injections. Physical
examination showed no evidence of neck disease and
pre-operative computed tomography (CT) imaging of
the head and neck showed no other evidence of disease.
The patient underwent salvage total laryngectomy and
bilateral neck dissection with final pathology revealing a
recurrent moderately differentiated SCC involving the
anterior larynx as well as metastatic prostate cancer in
draining level 4 cervical lymph nodes bilaterally. The
patient’s positron emission tomography (PET)/CT scan 3
months following salvage laryngectomy was positive for
only his known regional pelvic metastatic lymph nodes
with no evidence of FDG-avid locoregional tumor recur-
rence in the head and neck. We did not find circulating
adenocarcinoma tumor cells post-operatively on serum
analysis (Cell Tracks Analysis). The patient was seen in
follow-up 6 months following salvage laryngectomy with
no evidence of disease.
Methods
Two surgical pathologists independently confirmed the
diagnosis of metastatic prostate cancer to the cervical
lymph nodes. Sections 4 μm thick from formalin fixed
paraffin embedded tissue were placed on positively
charged slides, dried overnight at 65 °C and then stained
with the primary antibody CD163 (MRQ-26 clone, Cell
Marque, Rocklin, CA) on an automated platform (Ven-
tana, Tucson AZ). A pathologist reviewed all H&E
stained slides as well as positive and negative controls
for quality. Slides were uploaded into Aperio Imagescope
(Leica Biosystems, Buffalo Grove IL) and annotated by a
head and neck pathologist to include only the lymph
node portion for analysis. Quantitative analysis of
macrophage membrane staining was performed using
digital immunohistochemistry (IHC) analysis with
Aperio Imagescope to determine the percent of total
cells that stained strongly (2+, 3+) for CD163 for each
slide. This analytic algorithm has been FDA approved
for detecting hormonal receptors in breast cancer.
CD163 staining was performed on a benign draining
level three lymph node, a level four lymph node with a
focus of metastatic prostate cancer and the primary
laryngeal tumor. We compared this to 12 benign lymph
nodes of patients who underwent parotidectomy for
benign pathology.
Results
Descriptive pattern of staining for CD163 demonstrated a
paucity of M2 differentiation in the benign lymph nodes
of cancer-free parotidectomy patients (Fig. 1). Conversely,
the negative draining lymph node in the SCC patient with
metastatic prostate adenocarcinoma to the cervical lymph
nodes demonstrated a large CD163 population of cells
(Fig. 2), as did the interface of the metastatic focus of
prostate cancer and surrounding lymph node (Fig. 3).
Additionally, the macrophage differentiation at the
primary tumor in the larynx was strongly CD163 positive
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supporting an immune permissive environment for tumor
growth and metastasis (Fig. 4).
Table 1 shows the percent of total cells that stained
strongly for CD163 in the 12 benign parotid lymph node
controls as well as the CD163 levels of the negative
draining lymph node, lymph node with metastatic focus
of prostate adenocarcinoma, and primary tumor of our
patient. The average CD163 levels of the 12 patients
who underwent parotidectomy for benign pathology
with benign lymph nodes were 17.56%. In comparison,
the percent of cells that stained strongly for CD163 in
the negative level three draining lymph node was
62.94%. The CD163 level of the level four lymph node
with metastatic focus of prostate carcinoma was 42.91%.
The primary tumor had a CD163 level of 50.46%.
Discussion and conclusions
The incidence of cervical lymph node involvement in
patients with prostate cancer has been reported as 0.4%
or less and these patients almost uniformly present with
widespread metastatic disease [13, 14]. Despite the high
incidence and prevalence of prostate cancer, to the best
of our knowledge, there are less than 50 cases of pros-
tate cancer metastatic to the cervical lymph nodes
reported in the literature [14–21]. Furthermore, the ma-
jority of the cases involve a left supraclavicular lymph
node (Virchow’s node) [14, 20], and not necessarily
Fig. 1 CD163 staining in a reactive lymph node. Immunohistochemical
detection of CD163 cells in a benign lymph node of a cancer-free
parotidectomy patient demonstrates low levels of M2 differentiation
Fig. 2 CD163 staining in a negative draining lymph node from the
patient with laryngeal SCC and prostate adenocarcinoma metastatic
to the cervical lymph nodes. CD163 staining performed on a negative
draining lymph node in the SCC patient with metastatic prostate
adenocarcinoma to the cervical lymph nodes demonstrates a large
CD163 population
Fig. 3 CD163 staining in the lymph node with metastatic prostate
adenocarcinoma. CD163 staining performed on the lymph node
positive for metastatic prostate adenocarcinoma. The interface of the
metastatic focus of prostate adenocarcinoma and the surrounding
lymph node demonstrates dense CD163 staining
Fig. 4 CD163 staining in the primary laryngeal squamous cell carcinoma.
CD163 staining performed on the primary SCC tumor in the larynx.
Staining was strongly CD163 positive supporting an immune permissive
environment for tumor growth and metastasis
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lymph nodes in levels I-VI, a more common site of
metastasis in head and neck cancers.
We describe a unique case of metastatic prostate cancer
to cervical lymph nodes in the setting of a laryngeal SCC.
Our patient had no other foci of metastatic disease with
contained disease in the prostate and pelvic lymph nodes.
Additionally, serum from this patient did not reveal any
circulating prostate tumor cells (Cell Tracks Analysis)
supporting the argument that there may be a causative
relationship with lymph node priming from the laryngeal
primary opposed to simply a system overload with high
levels of circulating tumor cells. A review of the literature
revealed only two similar cases of prostate carcinoma
metastatic to the cervical lymph nodes in the setting of
concurrent HNSCC [21].
In the present report we show increased CD163 levels, a
marker for M2 macrophages, in both the negative drai-
ning lymph node, interface of the metastatic focus of pros-
tate cancer and surrounding lymph node, and primary
laryngeal tumor. When compared to benign lymph nodes
of patients who underwent parotidectomy for benign
pathology, the patient in this case report’s negative drai-
ning lymph node had CD163 levels that were three times
greater. In addition, our patient had high CD163 levels at
the primary tumor indicative of a predominant M2
phenotype, which suggests an immune permissive micro-
environment for tumor growth and metastasis.
Based on work done by Harshyne et al. in glioblastoma
[22], tumors communicate with the surrounding tumor
microenvironment via cytokines, exosomes, or other sol-
uble mediators. The elevated M2 macrophages both in the
positive lymph node as well as the negative draining
lymph node could fit this pattern of immune editing.
These observations could suggest that SCC may be able to
alter the tumor microenvironment both at the primary
tumor and draining lymph nodes favoring tumor escape
and metastasis. In the present case, we hypothesize that
the patient’s laryngeal SCC was able to communicate with
the local immune microenvironment to skew its pheno-
type to a permissive atmosphere allowing for occasional
circulating prostate cancer cells to metastasize to the
cervical lymph nodes.
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Table 1 Percent of total cells that stain strongly for CD163
Specimen CD163 Level
Benign parotid lymph node 1 4.79%
Benign parotid lymph node 2 13.61%
Benign parotid lymph node 3 37.84%
Benign parotid lymph node 4 10.08%
Benign parotid lymph node 5 10.01%
Benign parotid lymph node 6 26.93%
Benign parotid lymph node 7 18.84%
Benign parotid lymph node 8 12.84%
Benign parotid lymph node 9 23.33%
Benign parotid lymph node 10 29.16%
Benign parotid lymph node 11 14.78%
Benign parotid lymph node 12 8.52%
Average benign parotid lymph node 17.56%
Negative draining lymph node 62.94%
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